BioCentury | Oct 6, 2014
Finance

3Q14 Stock Wrap-Up: Going big again

...expected next year NovaBay Pharmaceuticals Inc. (NYSE-M:NBY) Discontinues development of an ophthalmic formulation of auriclosene (NVC-422...
BioCentury | Sep 1, 2014
Finance

Highlights of weekly biotech stock moves

...$0.44 (35%) to $0.81 on Aug. 20 after discontinuing development of an ophthalmic formulation of auriclosene...
...a Phase IIb trial. NovaBay said it will focus on developing an irrigation solution of auriclosene...
BioCentury | Sep 1, 2014
Clinical News

Auriclosene: Development discontinued

...NovaBay discontinued development of an ophthalmic formulation of auriclosene to treat adenoviral conjunctivitis after the product...
...to disclose detailed data. NovaBay said it will focus on developing an irrigation solution of auriclosene...
...BioCentury, Nov. 11, 2013). NovaBay Pharmaceuticals Inc. (NYSE-M:NBY), Emeryville, Calif. Product: Auriclosene ( CD07223 , NVC-422...
BioCentury | Aug 21, 2014
Clinical News

NovaBay falls after dropping auriclosene for conjunctivitis

...35%) to $0.81 on Wednesday after discontinuing development of an ophthalmic formulation of auriclosene ( NVC-422...
...trial in the indication. NovaBay said it will focus on developing an irrigation solution of auriclosene...
...the product's approval in the country. Galderma S.A. (Lausanne, Switzerland) has exclusive, worldwide rights to auriclosene...
BioCentury | Jun 9, 2014
Clinical News

Auriclosene: Completed Phase IIb enrollment

...auriclosene ophthalmic solution for 10 days. NovaBay plans to start a Phase II trial of auriclosene...
...S.A. (Lausanne, Switzerland) has exclusive, worldwide rights to develop and commercialize NovaBay's Aganocide compounds, including auriclosene...
...BioCentury, March 30, 2009). NovaBay Pharmaceuticals Inc. (NYSE-M:NBY), Emeryville, Calif. Product: Auriclosene ( CD07223 , NVC-422...
BioCentury | Jan 6, 2014
Finance

4Q Stock Wrap-Up: All's well that ends well

...than the rate for 2013 NovaBay Pharmaceuticals Inc. (NYSE-M:NBY)/Galderma S.A. A topical gel formulation of auriclosene...
BioCentury | Dec 23, 2013
Clinical News

Auriclosene: Phase IIb start

...Next year, NovaBay said it will begin evaluating an optimized formulation of auriclosene to treat patients...
...to treat patients with impetigo. In November, NovaBay reported that a topical gel formulation of auriclosene...
...S.A. , Lausanne, Switzerland NovaBay Pharmaceuticals Inc. (NYSE-M:NBY), Emeryville, Calif. Product: Auriclosene ( NVC-422 , CD07223...
BioCentury | Nov 11, 2013
Finance

Highlights of weekly biotech stock moves

...tumbled $0.78 (46%) to $0.91 on Thursday after its topical gel formulation of auriclosene ( NVC-422...
BioCentury | Nov 11, 2013
Clinical News

Auriclosene: Phase IIb data

...patients with impetigo showed that a topical gel formulation of auriclosene missed the primary endpoint. Auriclosene...
...next steps. Galderma has exclusive, worldwide rights to develop and commercialize NovaBay's Aganocide compounds, including auriclosene...
...S.A. , Lausanne, Switzerland NovaBay Pharmaceuticals Inc. (NYSE-M:NBY), Emeryville, Calif. Product: Auriclosene ( NVC-422 , CD07223...
BioCentury | Nov 7, 2013
Clinical News

NovaBay falls on impetigo miss

...NovaBay Pharmaceuticals Inc. (NYSE-M:NBY) said a topical gel formulation of the company's auriclosene ( NVC-422...
...develop and commercialize NovaBay's Aganocide compounds, including auriclosene, for impetigo, acne and other dermatological indications. Auriclosene...
Items per page:
1 - 10 of 59